https://doi.org/10.55788/ade97282
“RSV is a common cause of serious respiratory illness, especially in individuals with comorbidities,” said Dr Daniel Eiras (Pfizer, NY, USA). A bivalent stabilised RSV prefusion F vaccine was tested in the phase 3 RENOIR study (NCT05035212), in 38,861 participants who were at least 60 years of age [1]. All participants were healthy or had stable chronic conditions. They were randomised 1:1 to receive the RSV vaccine or a placebo. Dr Eiras and co-investigators followed patients for 2 years and documented all ‘acute respiratory illness’ events.
After 2 years, 10 events of RSV-lower respiratory tract illness were reported in the vaccinated arm compared with 54 events in the placebo arm. This reflects a vaccine efficacy of 81% across the 2 years (95% CI 63.3–91.6). In the first year, the vaccine’s efficacy was 88.9% and in the second year, the efficacy had dropped to 77.8%. The vaccine’s efficacy was consistent across subgroups, such as age groups, patients with high-risk conditions, and those with either RSV-A or RSV-B infections. “We observed robust immune responses for both RSV-A and RSV-B subgroups, as well as for patients with various cardiopulmonary conditions,” added Dr Eiras.
The findings of the RENOIR study show that the tested RSV vaccine has the potential to prevent serious respiratory illness in individuals who are at increased risk of serious illness after an RSV infection.
- Eiras D, et al. RSVpreF vaccine elicits a robust and durable immune response among adults aged 60 years and older. Late-breaking abstracts: science that will impact clinical care. ATS 2024, 17–22 May, San Diego, USA.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« UCAP: Identify and treat undiagnosed COPD or asthma Next Article
Patient-reported outcomes improve practice in MAC lung disease »
« UCAP: Identify and treat undiagnosed COPD or asthma Next Article
Patient-reported outcomes improve practice in MAC lung disease »
Table of Contents: ATS 2024
Featured articles
NOTUS: Dupilumab safe and efficacious in COPD with type 2 inflammation
Sulthiame may be the next treatment for OSA
Miscellaneous Topics
Pirfenidone may alleviate disease burden in DRCB
Can mindfulness reduce depression and anxiety in ICU survivors?
Exercise and diet improve functional status in PAH
Idiopathic Pulmonary Fibrosis
STARSCAPE: Zinpentraxin alfa does not ameliorate health status in IPF
COPD
COURSE: Encouraging results for tezepelumab in COPD
Ensifentrine delays transition from GOLD B to GOLD E in COPD
NOTUS: Dupilumab safe and efficacious in COPD with type 2 inflammation
BOREAS: Blood eosinophil count and FeNO levels predictive of dupilumab response in COPD
Respiratory Infections
Two regimens deliver high sputum conversion rates in M. xenopi pulmonary infection
Patient-reported outcomes improve practice in MAC lung disease
Novel RSV vaccine to prevent serious respiratory illness
Asthma
UCAP: Identify and treat undiagnosed COPD or asthma
Structural and functional lung improvement with dupilumab in asthma
Obstructive Sleep Apnea
Is the Apnea Hypopnea Index ready to be replaced?
Does PAP therapy truly reduce mortality in OSA?
Sulthiame may be the next treatment for OSA
Related Articles
September 21, 2020
AstraZeneca says Tagrisso shown to slow lung cancer spreading to brain
November 28, 2019
Orvepitant successful in decreasing symptoms of chronic cough
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com